ABIVAX Announces Its Financial Calendar for 2018

Regulatory News:

ABIVAX (Euronext Paris: FR0012333284 – ABVX) (Paris:ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today provides its planned financial calendar for 2018, which is set as follows:

* Subject to modification. Press releases are distributed either before the financial markets opening, or after the closure

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (www.abivax.com/en).

About ABIVAX (www.abivax.com)

ABIVAX is an innovative biotechnology company targeting the immune system to develop novel treatments for viral and inflammatory diseases as well as cancer. ABIVAX leverages three technology platforms for drug discovery: an antiviral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase 2 clinical trials for providing a sustained viral remission or functional cure for patients with HIV/AIDS. It is a first-in-class oral small antiviral molecule which blocks HIV replication through a unique mechanism of action and also has a strong anti-inflammatory effect, which is currently explored through a phase 2a proof-of-concept clinical trial in ulcerative colitis. In addition, ABIVAX is advancing a clinical stage immune enhancer for the treatment of cancer as well as multiple preclinical candidates against additional viral targets (e.g., Respiratory Syncytial Virus (RSV), Influenza and Dengue), and several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX).
More information on the company is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005028/en/